NKure Therapeutics based in Bangalore, is a pioneering cell and gene therapy company committed to revolutionizing cancer and infectious disease treatment in India. We are fuelled by a passionate team and funded by High-Net-worth individuals and institutional capital. Infectious diseases and cancers are both growing causes of concern in India. To combat this, various cell-based immunotherapies are garnering attention. However, it has been observed that many of these allogeneic therapies have significant complications such as graft versus host disease (GVHD) and cytokine storms that lead to prolonged hospitalisation. Therefore, existing therapies, especially in India, are mainly autologous. These therapies have low potential to scale up and hence, higher costs, which make them less affordable and accessible to the average Indian person in need of immunotherapy.
As a solution, NKure Therapeutics aims to introduce an off-the-shelf NK cell based immunotherapy as a multipronged approach to combat cancers and other maladies.
Our innovative approach focuses on creating scalable, accessible, and affordable off-the-shelf Natural Killer (NK) cell-based immunotherapies, while circumventing the limitations of current therapies. Through continuous research and development, we strive to provide hope and improved outcomes for countless patients while alleviating the financial burden on families affected by these devastating diseases. NK cells present fewer side effects than their counterparts, and allow for higher scalability. Therefore, NK cells give the desired outcome – lower costs that suit the growing Indian economy.
